DGAP-News: Evotec and the Jain Foundation announce extension of research collaboration in skeletal muscular dystrophy diseases
(firmenpresse) - DGAP-News: Evotec AG / Key word(s): Alliance
Evotec and the Jain Foundation announce extension of research
collaboration in skeletal muscular dystrophy diseases
21.08.2013 / 07:30
---------------------------------------------------------------------
Hamburg, Germany - 21 August 2013: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX, ISIN: DE0005664809) and the Jain Foundation today announced
that they have extended and expanded their research collaboration
leveraging Evotec's assay development and screening capabilities to support
the Jain Foundation's goals of understanding and curing dysferlinopathy.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: 'We look
forward to our continued collaboration with the Jain Foundation on this
project. This collaboration highlights both the increasing role that
foundations play in delivering solutions for unmet medical needs and also
how Evotec's broad and comprehensive discovery platform can be leveraged in
support of these goals in a highly efficient and effective manner.'
Dr Plavi Mittal, President and CEO of the Jain Foundation added: 'We are
excited to be moving toward screening compound libraries with Evotec. This
is an important step toward accomplishing our mission of finding a therapy
for Limb-girdle muscular dystrophy type 2B /Miyoshi Myopathy (LGMD2B/MM).'
No financial details were disclosed.
ABOUT THE EVOTEC AND JAIN FOUNDATION COLLABORATION
In 2012, Evotec and the Jain foundation initiated a research project to
develop a cell-based high throughput screening assay using dysferlin
deficient cells. The aim of this project is to develop a simple test for
the well-being of a muscle cell in the absence of dysferlin so that
compounds that improve the well-being of dysferlin deficient muscle cells
can be identified.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca
and Ono Pharmaceutical. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim,
MedImmune and Andromeda (Teva) in the field of diabetes, with Janssen
Pharmaceuticals in the field of depression and with Roche in the field of
Alzheimer's disease. For additional information please go to www.evotec.com
ABOUT JAIN FOUNDATION
The Jain Foundation, located in Bellevue Washington, USA, is a privately
funded not-for-profit focused on finding a therapy for muscular dystrophies
caused by dysferlin deficiency (LGMD2B/Miyoshi Myopathy).
ABOUT MUSCULAR DYSTROPHY
Muscular dystrophy refers to a group of diseases that produce muscle
weakness. Muscular dystrophies all involve abnormalities of the muscle
cells themselves, rather than the nerves that control the muscles. All
muscular dystrophies are caused by genetic mutations.
Limb-girdle muscular dystrophy refers to a group of diseases (not a single
disease) which were lumped together, long before the era of molecular
biology and genetic engineering, because they shared some common clinical
symptoms. The name refers to the first muscles to show symptoms, which are
those around the shoulders and the hips.
Myopathy simply means 'muscle disease.' Miyoshi Myopathy (MM) is a form of
muscular dystrophy that was first described in the medical literature by
Miyoshi in 1967. Although first identified in Japan, it occurs worldwide.
Miyoshi is caused by defects in the gene for the protein dysferlin.
Dysferlin is a protein made from the dysferlin gene that, when mutated or
absent, causes both Limb-Girdle Muscular Dystrophy type 2B and Miyoshi
Myopathy.
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, Head of Corporate Communications, Phone:
+49.(0)40.56081-255, gabriele.hansen(at)evotec.com
End of Corporate News
---------------------------------------------------------------------
21.08.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info(at)evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
226727 21.08.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 21.08.2013 - 07:30 Uhr
Sprache: Deutsch
News-ID 289554
Anzahl Zeichen: 13266
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 312 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Evotec and the Jain Foundation announce extension of research collaboration in skeletal muscular dystrophy diseases"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
